Canagliflozin Continues to be a Viable Treatment for Type 2 Diabetes

Canagliflozin Continues to be a Viable Treatment for Type 2 Diabetes

hemoglobin a1cOn January 16, 2015 the Journal of Diabetes and its Complications shared positive findings from a recent post hoc analysis of Canagliflozin. Comprehensive data was analyzed from Phase 3 studies of Canagliflozin in adult patients with type 2 diabetes. This placebo-controlled study was comprised of four 26 week periods, with changes in HbA1c being sought by the end of each 26 week segment. Canagliflozin proved to be successful in lowering the HbA1c of the participants as well as showing overall glycemic improvements. Dosages of 100 milligrams and 300 milligrams of Canagliflozin elicited significantly greater reductions in HbA1c as compared to the patients who were administered a placebo. Additionally, patients tolerated Canagliflozin well and the safety profile of this anti diabetic therapy was tangible. As an effectual sodium glucose co–transporter 2 inhibitor Canagliflozin has performed remarkably in a vast number of studies over the last decade.

Another recent article focused on the positive effects of Canagliflozin, published in the January 20, 2015 issue of Diabetes, Obesity & Metabolism. The information disseminated revealed a sizable reduction on serum uric acid in patients with type 2 diabetes mellitus who were given Canagliflozin in studies. An increase in uric acid, also known as Hyperuricaemia can often lead to complications from type 2 diabetes, such as kidney stones and gout. Information gleaned from four Phase 3 studies showed a reduction of 13 percent on serum uric acid levels for patients who were administered Canagliflozin, as compared to a placebo. The reduction was apparent at week 26 of the studies on average, and patients who saw these reductions also experienced a major decrease of incidences with gout and kidney stones. Of the patients who received 100 milligrams of Canagliflozin 23.5 percent of these participants saw a viable reduction in serum uric acid levels. Approximately 32.4 percent of participants who were dosed with 300 milligrams daily of Canagliflozin experienced a worthy reduction in serum uric acid levels. Patients in the placebo group had a mere 3.1 percent reduction in their uric acid levels at the 26 week mark.

canagliflozinKnown as the brand name Invokana, which is marketing by Janssen, Canagliflozin is an oral medication used to treat type 2 diabetes. Patients with type 1, or juvenile diabetes, should not take Canagliflozin. In addition to diet and exercise Canagliflozin has shown to be a safe and effective treatment for adult patients with type 2 diabetes who cannot control their glucose levels. Canagliflozin is typically taken once daily by mouth. Adverse effects are uncommon, with most commonly reported side effects being nausea, constipation and frequent urination. LGM Pharma can assist clients as a supplier/distributor of the API Canagliflozin, CAS # 842133-18-0, for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service